Clinical Trial Update: A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis [Phase 1]

View source ↗

Summary

Phase 1 study of inhaled SNSP113 in healthy subjects and individuals with stable cystic fibrosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• SNSP113

Snippet

Sponsor: Synspira, Inc. | Conditions: Lung Diseases, Pulmonary Disease | Phase 1 | Status: TERMINATED